Breakingviews - Biotech undergoes the ultimate trial by epidemic
HONG KONG (Reuters Breakingviews) - A new coronavirus epidemic puts promising but untested science under a microscope. Biotech stars like the $7.7 billion Moderna boast new tech that would cut costs and time to find a vaccine. As the world grapples to contain a deadly new virus, they have a rare chance to demonstrate proof of concept.
